Literature DB >> 18954590

Diagnosis and treatment of depression comorbid with neurologic disorders.

Murray A Raskind1.   

Abstract

Depression is common in patients with neurologic disorders such as Alzheimer disease, stroke, Parkinson disease, and multiple sclerosis. Diagnosing depression in the context of neurologic disease is challenging, given the overlap between many signs and symptoms of depression with those of the neurologic disorders. Cognitive impairment further complicates diagnostic evaluation. The etiology of depression in these patients is not well understood and variously has been attributed to emotional reaction to the diagnosis or disability associated with the neurologic condition, the anatomical and/or neurochemical outcomes of neurodegeneration, and the influence of other disease factors. Beyond the inherent burden depression places on patients and caregivers, it increases cognitive and functional disability and, depending on the neurologic disorder, poorer treatment adherence and recovery, earlier institutionalization, and increased suicide risk. Few controlled antidepressant trials are available to guide treatment. In the absence of validated diagnostic guidelines for depression in each neurologic condition, clinicians are urged to remain vigilant for this treatable comorbidity. Although more controlled trials clearly are needed, existing studies suggest that depression in patients with neurologic disorders responds to antidepressant medication and, in some disorders, to psychotherapeutic approaches. Investigating the neuroanatomical and neurochemical correlates of depression comorbid with neurologic conditions also may clarify depression etiology and treatment in the general population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18954590     DOI: 10.1016/j.amjmed.2008.09.011

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  21 in total

1.  Treatment of mood disorders in multiple sclerosis.

Authors:  Luis Pintor Pérez; Roberto Sánchez González; Eva Baillés Lázaro
Journal:  Curr Treat Options Neurol       Date:  2015-01       Impact factor: 3.598

2.  Neuroprotective Effects of Antidepressants via Upregulation of Neurotrophic Factors in the MPTP Model of Parkinson's Disease.

Authors:  Sina Shadfar; Yu-Gyeong Kim; Nikita Katila; Sabita Neupane; Uttam Ojha; Sunil Bhurtel; Sunil Srivastav; Gil-Saeng Jeong; Pil-Hoon Park; Jin Tae Hong; Dong-Young Choi
Journal:  Mol Neurobiol       Date:  2016-12-14       Impact factor: 5.590

3.  Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study.

Authors:  Eric A Epping; James A Mills; Leigh J Beglinger; Jess G Fiedorowicz; David Craufurd; Megan M Smith; Mark Groves; Kelly R Bijanki; Nancy Downing; Janet K Williams; Jeffrey D Long; Jane S Paulsen
Journal:  J Psychiatr Res       Date:  2013-06-19       Impact factor: 4.791

Review 4.  Neuroinflammation, neurodegeneration, and depression.

Authors:  Laura L Hurley; Yousef Tizabi
Journal:  Neurotox Res       Date:  2012-08-16       Impact factor: 3.911

5.  Comparison of two depression measures for predicting stroke outcomes.

Authors:  Lawson Wulsin; Kathleen Alwell; Charles J Moomaw; Christopher J Lindsell; Dawn O Kleindorfer; Daniel Woo; Matthew L Flaherty; Pooja Khatri; Opeolu Adeoye; Simona Ferioli; Joseph P Broderick; Brett M Kissela
Journal:  J Psychosom Res       Date:  2012-01-14       Impact factor: 3.006

Review 6.  Suicide in stroke survivors: epidemiology and prevention.

Authors:  Maurizio Pompili; Paola Venturini; Dorian A Lamis; Gloria Giordano; Gianluca Serafini; Martino Belvederi Murri; Mario Amore; Paolo Girardi
Journal:  Drugs Aging       Date:  2015-01       Impact factor: 3.923

7.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

8.  Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice.

Authors:  Yan Hou; Marwa A Aboukhatwa; De-Liang Lei; Kebreten Manaye; Ikhlas Khan; Yuan Luo
Journal:  Neuropharmacology       Date:  2009-11-14       Impact factor: 5.250

9.  Neurologic provider views on patient-reported outcomes including depression screening.

Authors:  Irene L Katzan; Nicolas R Thompson; Cheryl Dunphy; John Urchek; Brittany Lapin
Journal:  Neurol Clin Pract       Date:  2018-04

10.  Altered Cerebral Blood Flow in Alzheimer's Disease With Depression.

Authors:  Runzhi Li; Yanling Zhang; Zhizheng Zhuo; Yanli Wang; Ziyan Jia; Mengfan Sun; Yuan Zhang; Wenyi Li; Yunyun Duan; Zeshan Yao; Haoyi Weng; Juan Wei; Yaou Liu; Jun Xu
Journal:  Front Psychiatry       Date:  2021-07-08       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.